FibroBiologics, Inc.
FBLG
$1.06
-$0.09-7.83%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 8.53M | 8.61M | 9.24M | 9.81M | 9.70M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 16.73M | 17.19M | 16.65M | 17.77M | 16.09M |
| Operating Income | -16.73M | -17.19M | -16.65M | -17.77M | -16.09M |
| Income Before Tax | -18.14M | -18.68M | -18.65M | -18.50M | -13.22M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -18.14 | -18.68 | -18.65 | -18.50 | -13.22 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -18.14M | -18.68M | -18.65M | -18.50M | -13.22M |
| EBIT | -16.73M | -17.19M | -16.65M | -17.77M | -16.09M |
| EBITDA | -16.47M | -16.93M | -16.41M | -17.55M | -15.89M |
| EPS Basic | -5.93 | -7.69 | -9.07 | -9.84 | -7.34 |
| Normalized Basic EPS | -3.71 | -4.80 | -5.67 | -6.15 | -4.59 |
| EPS Diluted | -5.93 | -7.69 | -9.07 | -9.84 | -7.34 |
| Normalized Diluted EPS | -3.71 | -4.80 | -5.67 | -6.15 | -4.59 |
| Average Basic Shares Outstanding | 118.46M | 114.12M | 112.18M | 84.83M | 74.79M |
| Average Diluted Shares Outstanding | 118.46M | 114.12M | 112.18M | 84.83M | 74.79M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |